Potential future treatment strategies for retinal vein occlusion

被引:1
作者
Shuler, R. Keith, Jr. [1 ]
Fekrat, Sharon [2 ]
机构
[1] Duke Univ, Duke Univ Eye Ctr, Dept Ophthalmol, DUMC Box 3802,Erwin Rd, Durham, NC 27710 USA
[2] Duke Univ, Duke Univ Eye Ctr, Dept Ophthalmol, Vitreoretinal Serv, Durham, NC 27710 USA
关键词
branch retinal vein occlusion; central retinal vein occlusion; retinal vein occlusion; treatment;
D O I
10.1586/17469899.1.1.77
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Our understanding of the pathophysiology of retinal venous occlusive disease is limited and the number of proven therapies is even more so. As a result, there is a growing number of unproven treatment strategies. The majority of these unproven treatments attempt to reduce the macular edema, which is a consequence of the vein occlusion, but few attempt to improve the underlying retinal venous outflow, retinal perfusion and oxygenation. A more thorough knowledge of the natural history is needed to better determine any actual therapeutic benefit of these current treatments. A greater knowledge of the molecular and hemodynamic pathophysiology is also required to allow the development of future treatment strategies. In this article, pharmacological and surgical treatment strategies are reviewed, as well as selected ongoing clinical trials for retinal venous occlusions.
引用
收藏
页码:77 / 82
页数:6
相关论文
共 50 条
[41]   ENDOTHELIN-1 AS A RISK FACTOR IN RETINAL VEIN OCCLUSION [J].
List, Wolfgang ;
Weger, Martin ;
Pinter-Hausberger, Silke ;
Posch, Florian ;
Rabensteiner, Jasmin ;
Pailer, Sabine ;
Wedrich, Andreas ;
Posch-Pertl, Laura .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (04) :738-743
[42]   Hyperfluorescence at arteriovenous crossing before branch retinal vein occlusion [J].
Parodi, MB .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2002, 240 (01) :67-67
[43]   Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion [J].
W. Lloyd Clark ;
Mimi Liu ;
John Kitchens ;
Pin-wen Wang ;
Zdenka Haskova .
BMC Ophthalmology, 19
[44]   Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion [J].
Clark, W. Lloyd ;
Liu, Mimi ;
Kitchens, John ;
Wang, Pin-wen ;
Haskova, Zdenka .
BMC OPHTHALMOLOGY, 2019, 19 (1)
[45]   Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion [J].
Cinal, Adnan ;
Ziemssen, Focke ;
Bartz-Schmidt, Karl U. ;
Gelisken, Faik .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 249 (04) :513-520
[46]   Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion [J].
Adnan Cinal ;
Focke Ziemssen ;
Karl U. Bartz-Schmidt ;
Faik Gelisken .
Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249 :513-520
[47]   Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment [J].
Dan Călugăru ;
Mihai Călugăru .
Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 :2477-2478
[48]   Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion [J].
Khayat, Meiaad ;
Williams, Michael ;
Lois, Noemi .
SURVEY OF OPHTHALMOLOGY, 2018, 63 (06) :816-850
[49]   Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex((R))) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion [J].
Chan, Annie ;
Leung, Loh-Shan ;
Blumenkranz, Mark S. .
CLINICAL OPHTHALMOLOGY, 2011, 5 :1043-1049
[50]   RETINAL SENSITIVITY AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION [J].
Yamaike, Noritatsu ;
Tsujikawa, Akitaka ;
Sakamoto, Atsushi ;
Ota, Masafumi ;
Kotera, Yuriko ;
Miyamoto, Kazuaki ;
Kita, Mihori ;
Yoshimura, Nagahisa .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (06) :757-767